Progenics Pharmaceuticals, Inc. (PGNX) said it has opened enrollment in a phase 2 study in prostate cancer patients of its PSMA ADC compound. PSMA ADC is a targeted anti-cancer therapeutic that uses a monoclonal antibody to deliver a cell-killing drug to malignant cells.
The phase 2 trial is an open-label, multicenter study to assess the anti-tumor activity and tolerability of PSMA ADC in up to 75 subjects with metastatic castration-resistant prostate cancer. Patients will receive a total of eight doses of drug at 2.5 mg/kg. The study endpoints assess responses in prostate specific antigen, circulating tumor cells, bone, visceral and nodal metastases and pain. Safety also will be assessed.
For comments and feedback: editorial@rttnews.com